Closing
Do other cardiovascular drugs improve all-cause mortality more than other treatments?
Mostly studied in coronary & atherosclerotic disease.
Not modeled yetTrial evidence exists, but no mechanistic model yetWithout a model there is no decisive experiment to propose. Help build it. →
Where the evidence stands
A coin flip. So far, one result, not yet repeated.
NoUnsureYes
- Belief
- 0.50 (range 0.25–0.70)
- Trials for
- 1
- Trials against
- 0
- Inconclusive
- 0
Already under way
- Feasibility Trial for the Canadian Right Ventricular AdaptiVE (CRAVE) Platform for Therapies Targeting Right Ventricular FailureNCT06570473 · recruiting · started 2025
- Evaluation of a POlypill and Colchicine for Risk Reduction in Patients With Established Atherosclerotic Cardiovascular Disease: The EPOCA Randomized Clinical…NCT06930885 · recruiting · started 2025
The evidence so far
- Registered trials
- 10
- With posted results
- 3
- Published papers
- 1
Of 2 decided analyses: 2 favor other cardiovascular drugs, 0 find no difference, 0 favor the comparator.
Papers
- The interaction among OSA, CPAP, and medications in patients with comorbid OSA and cardiovascular/cerebrovascular disease: a randomized controlled trial.Trial report · 2022
Trials
- Study of Curative Effect Evaluation of DanLou Tablet on Coronary Artery Disease Not Amenable to Revascularization on the Basis of Western Medicine TherapyNCT03072082
- Study of Curative Effect Evaluation of Shexiang Baoxin Pill on Coronary Artery Disease Not Amenable to Revascularization on the Basis of Western Medicine TherapyNCT03072121
- Evaluation of a POlypill and Colchicine for Risk Reduction in Patients With Established Atherosclerotic Cardiovascular Disease: The EPOCA Randomized Clinical TrialNCT06930885
- Effect of Pioglitazone on Insulin Resistance, Progression of Atherosclerosis and Clinical Course of Coronary Heart DiseaseNCT03011775 · 1 posted result
- Impact of Sodium-glucose Cotransporter Type 2 Inhibitors on the Course of Cardiorenal Syndrome in Acute Decompensation of Chronic Heart FailureNCT04778787
- A Multi Center, Randomized, Double Blind, Placebo-controlled, Dose Escalation Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ACZ885 Administered Intravenously to Patients With Type 2 Diabetes MellitusNCT00605475 · 1 posted result
- A Randomized, Double-blind, Placebo Controlled Study (DANHEART): Hydralazine-ISDN in Patients With Chronic Heart Failure - Hydralazine Heart Failure Trial (H-HeFT) and Metformin in Patients With Chronic Heart Failure and Diabetes or Insulin Resistance - Metformin Heart Failure Trial (Met-HeFT)NCT03514108
- Combination Effects of High-dose Statin and Trimetazidine on Patients With Aspirin Mono Antiplatelet Therapy 12-months After Coronary Artery Bypass SurgeryNCT01857921